Back to MW Marshall Wace, LLP

KNSAKNSA

8 quarters

Position history for MWMarshall Wace, LLP's holdings in Kiniksa Pharmaceuticals International, plc

No. Marshall Wace exited its KNSA (Kiniksa Pharmaceuticals International) position in Q2 2026. Its Q1 2026 13F listed 305,371 shares worth $14.7M. Marshall Wace first reported KNSA in Q3 2024 and held it in 6 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$2.3M

Total Shares Change

-90,571

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Exited
0
-100.0%
$00.0%$63.95
0
2026-Q1
Increased
305,371
+5165.0%
$14.7M0.0%$48.15
45
2025-Q4
Decreased
5,800
-90.5%
$239,2500.0%$41.25
0
2025-Q3
Decreased
61,316
-19.7%
$2.4M0.0%$38.83
0
2025-Q2
New
76,347
—
$2.1M0.0%$27.67
36
2025-Q1
Exited
0
-100.0%
$00.0%$22.21
0
2024-Q4
Decreased
86,762
-4.2%
$1.7M0.0%$19.78
0
2024-Q3
New
90,571
—
$2.3M0.0%$24.99
36

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used